Does the media prefer IBRX or CLDX?

In the previous week, ImmunityBio had 5 more articles in the media than Celldex Therapeutics. MarketBeat recorded 8 mentions for ImmunityBio and 3 mentions for Celldex Therapeutics. ImmunityBio's average media sentiment score of 0.67 beat Celldex Therapeutics' score of 0.18 indicating that ImmunityBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Celldex Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer PTGX or CLDX?

In the previous week, Celldex Therapeutics had 1 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 3 mentions for Celldex Therapeutics and 2 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.83 beat Celldex Therapeutics' score of 0.18 indicating that Protagonist Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Celldex Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer CLDX or KYMR?

In the previous week, Kymera Therapeutics had 1 more articles in the media than Celldex Therapeutics. MarketBeat recorded 4 mentions for Kymera Therapeutics and 3 mentions for Celldex Therapeutics. Kymera Therapeutics' average media sentiment score of 0.34 beat Celldex Therapeutics' score of 0.18 indicating that Kymera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celldex Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kymera Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer CLDX or ARWR?

In the previous week, Arrowhead Pharmaceuticals had 2 more articles in the media than Celldex Therapeutics. MarketBeat recorded 5 mentions for Arrowhead Pharmaceuticals and 3 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 0.18 beat Arrowhead Pharmaceuticals' score of 0.17 indicating that Celldex Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celldex Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arrowhead Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PCVX or CLDX more profitable?

Vaxcyte's return on equity of -37.56% beat Celldex Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Vaxcyte N/A -37.56% -33.62% Celldex Therapeutics N/A -52.35% -47.61%

Does the media favor PCVX or CLDX?

In the previous week, Celldex Therapeutics had 1 more articles in the media than Vaxcyte. MarketBeat recorded 3 mentions for Celldex Therapeutics and 2 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 0.33 beat Celldex Therapeutics' score of 0.18 indicating that Vaxcyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Celldex Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Celldex Therapeutics (CLDX) Competitors

$31.66 -0.52 (-1.63%)

Closing price 03:59 PM Eastern

Extended Trading

$31.66 +0.01 (+0.03%)

As of 04:10 PM Eastern

Compare

CLDX vs. IBRX, PTGX, KYMR, ARWR, and PCVX

Should you buy Celldex Therapeutics stock or one of its competitors? Celldex Therapeutics's main competitors and comparable companies include ImmunityBio (IBRX), Protagonist Therapeutics (PTGX), Kymera Therapeutics (KYMR), Arrowhead Pharmaceuticals (ARWR), and Vaxcyte (PCVX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Celldex Therapeutics compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and Celldex Therapeutics (NASDAQ:CLDX) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

ImmunityBio has a beta of 0.02, indicating that its share price is 98% less volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market.

In the previous week, ImmunityBio had 5 more articles in the media than Celldex Therapeutics. MarketBeat recorded 8 mentions for ImmunityBio and 3 mentions for Celldex Therapeutics. ImmunityBio's average media sentiment score of 0.67 beat Celldex Therapeutics' score of 0.18 indicating that ImmunityBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Celldex Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

8.6% of ImmunityBio shares are held by institutional investors. 66.1% of ImmunityBio shares are held by company insiders. Comparatively, 5.2% of Celldex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Celldex Therapeutics has a net margin of 0.00% compared to ImmunityBio's net margin of -598.55%. ImmunityBio's return on equity of 0.00% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-598.55%	N/A	-51.65%
Celldex Therapeutics	N/A	-52.35%	-47.61%

ImmunityBio currently has a consensus target price of $14.20, suggesting a potential upside of 38.63%. Celldex Therapeutics has a consensus target price of $61.92, suggesting a potential upside of 92.91%. Given Celldex Therapeutics' higher probable upside, analysts plainly believe Celldex Therapeutics is more favorable than ImmunityBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Celldex Therapeutics has lower revenue, but higher earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	95.82	-$351.40M	-$0.97	N/A
Celldex Therapeutics	$1.54M	1,636.89	-$258.76M	-$4.35	N/A

Summary

Celldex Therapeutics beats ImmunityBio on 8 of the 15 factors compared between the two stocks.

How does Celldex Therapeutics compare to Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ:PTGX) and Celldex Therapeutics (NASDAQ:CLDX) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Protagonist Therapeutics presently has a consensus price target of $147.13, suggesting a potential upside of 5.36%. Celldex Therapeutics has a consensus price target of $61.92, suggesting a potential upside of 92.91%. Given Celldex Therapeutics' higher probable upside, analysts clearly believe Celldex Therapeutics is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	0 Sell rating(s)	2 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.89
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

In the previous week, Celldex Therapeutics had 1 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 3 mentions for Celldex Therapeutics and 2 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.83 beat Celldex Therapeutics' score of 0.18 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Celldex Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Protagonist Therapeutics has a net margin of 29.40% compared to Celldex Therapeutics' net margin of 0.00%. Protagonist Therapeutics' return on equity of 12.03% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	29.40%	12.03%	11.23%
Celldex Therapeutics	N/A	-52.35%	-47.61%

Protagonist Therapeutics has a beta of 1.53, suggesting that its stock price is 53% more volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market.

Protagonist Therapeutics has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02M	196.36	-$130.15M	$1.03	135.58
Celldex Therapeutics	$1.54M	1,636.89	-$258.76M	-$4.35	N/A

98.6% of Protagonist Therapeutics shares are held by institutional investors. 5.2% of Protagonist Therapeutics shares are held by company insiders. Comparatively, 5.2% of Celldex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Protagonist Therapeutics beats Celldex Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Celldex Therapeutics compare to Kymera Therapeutics?

Celldex Therapeutics (NASDAQ:CLDX) and Kymera Therapeutics (NASDAQ:KYMR) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Celldex Therapeutics has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$1.54M	1,636.89	-$258.76M	-$4.35	N/A
Kymera Therapeutics	$39.21M	228.60	-$311.35M	-$3.24	N/A

In the previous week, Kymera Therapeutics had 1 more articles in the media than Celldex Therapeutics. MarketBeat recorded 4 mentions for Kymera Therapeutics and 3 mentions for Celldex Therapeutics. Kymera Therapeutics' average media sentiment score of 0.34 beat Celldex Therapeutics' score of 0.18 indicating that Kymera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celldex Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kymera Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Celldex Therapeutics has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -285.33%. Kymera Therapeutics' return on equity of -21.22% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	N/A	-52.35%	-47.61%
Kymera Therapeutics	-285.33%	-21.22%	-19.21%

Celldex Therapeutics has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 1.98, indicating that its share price is 98% more volatile than the broader market.

Celldex Therapeutics presently has a consensus price target of $61.92, suggesting a potential upside of 92.91%. Kymera Therapeutics has a consensus price target of $133.21, suggesting a potential upside of 23.57%. Given Celldex Therapeutics' higher probable upside, research analysts plainly believe Celldex Therapeutics is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Kymera Therapeutics beats Celldex Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Celldex Therapeutics compare to Arrowhead Pharmaceuticals?

Celldex Therapeutics (NASDAQ:CLDX) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

Celldex Therapeutics presently has a consensus price target of $61.92, suggesting a potential upside of 92.91%. Arrowhead Pharmaceuticals has a consensus price target of $98.31, suggesting a potential upside of 52.36%. Given Celldex Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Celldex Therapeutics is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64

62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 5.2% of Celldex Therapeutics shares are owned by company insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Celldex Therapeutics has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -47.79%. Celldex Therapeutics' return on equity of -52.35% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	N/A	-52.35%	-47.61%
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%

Celldex Therapeutics has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.3, suggesting that its share price is 30% more volatile than the broader market.

In the previous week, Arrowhead Pharmaceuticals had 2 more articles in the media than Celldex Therapeutics. MarketBeat recorded 5 mentions for Arrowhead Pharmaceuticals and 3 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 0.18 beat Arrowhead Pharmaceuticals' score of 0.17 indicating that Celldex Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celldex Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arrowhead Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Arrowhead Pharmaceuticals has higher revenue and earnings than Celldex Therapeutics. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$1.54M	1,636.89	-$258.76M	-$4.35	N/A
Arrowhead Pharmaceuticals	$829.45M	10.96	-$1.63M	-$2.25	N/A

Summary

Celldex Therapeutics beats Arrowhead Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Celldex Therapeutics compare to Vaxcyte?

Vaxcyte (NASDAQ:PCVX) and Celldex Therapeutics (NASDAQ:CLDX) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership and risk.

Vaxcyte's return on equity of -37.56% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-37.56%	-33.62%
Celldex Therapeutics	N/A	-52.35%	-47.61%

Vaxcyte currently has a consensus target price of $104.40, suggesting a potential upside of 84.45%. Celldex Therapeutics has a consensus target price of $61.92, suggesting a potential upside of 92.91%. Given Celldex Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Celldex Therapeutics is more favorable than Vaxcyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

In the previous week, Celldex Therapeutics had 1 more articles in the media than Vaxcyte. MarketBeat recorded 3 mentions for Celldex Therapeutics and 2 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 0.33 beat Celldex Therapeutics' score of 0.18 indicating that Vaxcyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Celldex Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vaxcyte has a beta of 1.23, suggesting that its stock price is 23% more volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market.

96.8% of Vaxcyte shares are owned by institutional investors. 3.3% of Vaxcyte shares are owned by insiders. Comparatively, 5.2% of Celldex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Celldex Therapeutics has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$7.63	N/A
Celldex Therapeutics	$1.54M	1,636.89	-$258.76M	-$4.35	N/A

Summary

Celldex Therapeutics beats Vaxcyte on 10 of the 15 factors compared between the two stocks.

Get Celldex Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLDX vs. The Competition

Export

Metric	Celldex Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.49B	$3.84B	$7.11B	$13.24B
Dividend Yield	N/A	3.64%	2.53%	15.88%
P/E Ratio	-7.28	13.44	274.42	26.03
Price / Sales	1,614.25	1,285.38	600.72	89.51
Price / Cash	N/A	121.76	77.38	51.25
Price / Book	3.99	16.64	10.92	6.32
Net Income	-$258.76M	-$22.67M	$3.50B	$361.43M
7 Day Performance	1.79%	-2.99%	-2.07%	-1.66%
1 Month Performance	-19.82%	-10.68%	-6.32%	-3.93%
1 Year Performance	22.46%	21.44%	8.92%	2.82%

Celldex Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLDX Celldex Therapeutics	2.0234 of 5 stars	$31.66 -1.6%	$61.92 +95.6%	+27.2%	$2.49B	$1.54M	N/A	198	Analyst Forecast
IBRX ImmunityBio	2.8331 of 5 stars	$8.64 +1.4%	$14.20 +64.3%	+274.2%	$9.35B	$113.29M	N/A	691
PTGX Protagonist Therapeutics	1.6878 of 5 stars	$140.81 -1.1%	$147.13 +4.5%	+117.5%	$9.26B	$46.02M	138.98	141
KYMR Kymera Therapeutics	2.0088 of 5 stars	$111.05 -0.8%	$133.21 +20.0%	+101.5%	$9.23B	$39.21M	N/A	273	Insider Trade
ARWR Arrowhead Pharmaceuticals	2.9549 of 5 stars	$65.27 -0.3%	$98.31 +50.6%	+85.1%	$9.22B	$829.45M	N/A	711

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLDX) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Celldex Therapeutics (CLDX) Competitors

CLDX vs. IBRX, PTGX, KYMR, ARWR, and PCVX

How does Celldex Therapeutics compare to ImmunityBio?

Summary

How does Celldex Therapeutics compare to Protagonist Therapeutics?

Summary

How does Celldex Therapeutics compare to Kymera Therapeutics?

Summary

How does Celldex Therapeutics compare to Arrowhead Pharmaceuticals?

Summary

How does Celldex Therapeutics compare to Vaxcyte?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLDX vs. The Competition

Celldex Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Celldex Therapeutics (CLDX) Competitors

CLDX vs. IBRX, PTGX, KYMR, ARWR, and PCVX

How does Celldex Therapeutics compare to ImmunityBio?

Which has more volatility and risk, IBRX or CLDX?

Does the media prefer IBRX or CLDX?

Do institutionals & insiders have more ownership in IBRX or CLDX?

Is IBRX or CLDX more profitable?

Do analysts recommend IBRX or CLDX?

Which has preferable earnings & valuation, IBRX or CLDX?

Summary

How does Celldex Therapeutics compare to Protagonist Therapeutics?

Do analysts recommend PTGX or CLDX?

Does the media prefer PTGX or CLDX?

Is PTGX or CLDX more profitable?

Which has more risk and volatility, PTGX or CLDX?

Which has better earnings and valuation, PTGX or CLDX?

Do insiders and institutionals have more ownership in PTGX or CLDX?

Summary

How does Celldex Therapeutics compare to Kymera Therapeutics?

Which has higher earnings and valuation, CLDX or KYMR?

Does the media prefer CLDX or KYMR?

Is CLDX or KYMR more profitable?

Which has more risk & volatility, CLDX or KYMR?

Do analysts prefer CLDX or KYMR?

Summary

How does Celldex Therapeutics compare to Arrowhead Pharmaceuticals?

Do analysts recommend CLDX or ARWR?

Do insiders & institutionals have more ownership in CLDX or ARWR?

Is CLDX or ARWR more profitable?

Which has more volatility & risk, CLDX or ARWR?

Does the media prefer CLDX or ARWR?

Which has better valuation & earnings, CLDX or ARWR?

Summary

How does Celldex Therapeutics compare to Vaxcyte?

Is PCVX or CLDX more profitable?

Do analysts prefer PCVX or CLDX?

Does the media favor PCVX or CLDX?

Which has more volatility and risk, PCVX or CLDX?

Do insiders & institutionals hold more shares of PCVX or CLDX?

Which has better valuation and earnings, PCVX or CLDX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLDX vs. The Competition

Celldex Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools